Navigation Links
New drug candidate knocks out resistant form of chronic myeloid leukemia
Date:12/10/2007

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).

This drug candidate could build on the legacy of Gleevec, which has been the gold standard for treating this leukemia and was developed by Brian Druker, M.D., director of the OHSU Cancer Institute. Despite Gleevecs success, some CML patients develop resistance to Gleevec, often due to mutations that interfere with drug binding. The second-generation drugs Sprycel and Tasigna have been developed as largely successful treatments for Gleevec-resistant patients. However, one mutation, termed T315I, is completely resistant to all three clinical CML drugs and is a frequent cause of relapse.

Now, however, a new drug candidate, SGX393, has been found to inhibit most resistant mutations, including T315I, both in mouse models and in patient cells in laboratory studies. SGX393 was identified by SGX Pharmaceuticals Inc., a biotechnology company focusing on cancer therapeutics.

The OHSU Cancer Institute researchers took this a step further.

Because none of the drugs controlled all of the known mutations, we extended our study to look at using combinations of the drugs, said Christopher Eide, research technician, hematology/medical oncology, OHSU School of Medicine.

Remarkably, we found that the combination of SGX393 with either Sprycel or Tasigna completely suppressed resistant growth. Our findings raise the exciting possibility that inhibitor cocktails may be sufficient to completely pre-empt drug resistance in CML, Eide said.

He is a co-author with OHSU Cancer Institute research scientist Thomas OHare, Ph.D., research specialist, hematology/medical oncology, OHSU School of Medicine.

The study was performed in the laboratory of Michael Deininger, M.D., Ph.D., associate professor of medicine, hematology/medical oncology, OHSU School of Medicine.

What patients should know is that, with the addition of this drug candidate to the currently available set of clinical CML drugs, we may have the therapeutic tools to achieve and maintain even more effective and longer control of their disease, Bumm said.

Gleevec continues to be remarkably successful in the vast majority of patients. However, for those patients who develop resistance, incorporating a targeted T315I inhibitor such as SGX393 into the suite of available CML drugs in the clinic is urgently needed. This is not equivalent to cure, but it could potentially represent an important advance in disease management with CML inhibitor therapy.

SGX Pharmaceuticals, Inc. is targeting submitting an Investigational New Drug application for SGX393 in the first half of 2008.

OHSU has licensed some of the underlying technology used in this research to MolecularMD.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. U.S. Physicians Question Presidential Candidates
5. Schizophrenia candidate genes affect even healthy individuals
6. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Data on Avicenas Drug Candidate HD-02 Presented at the 2007 World Congress on Huntingtons Disease
9. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
10. 1 in 5 bariatric surgery candidates not psychologically cleared for surgery
11. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... ... offices in Pasco and Richland, is initiating a charity drive to support the ... from a recent automobile collision. , On October 29th of this year, ...
(Date:12/9/2016)... ... 2016 , ... The Justin Veatch Fund announced Thursday that ... film Whispering Spirits and its discussion guide for use by all of ... in the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate that ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Australia Ophthalmic Lasers Market Outlook to 2022 ... Outlook to 2022", provides key market data on the ... millions of US dollars, volume (in units) and average ... Lasers and YAG Lasers. The report also provides ... these market segements, and global corporate-level profiles of the ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
Breaking Medicine Technology: